A pproximately 800 genes in humans are dedicated to the production of a large superfamily of seven-transmembrane ␣-helical receptors called G proteincoupled receptors (GPCRs) (1) . These proteins are responsible for the intracellular chemical communication and for the sensory input by chemical stimuli (smell and taste). Consistent with their central role in human physiology, GPCRs constitute the largest class of targets for drug discovery with approximately one-third of all approved therapeutics acting by modulating GPCR function (1) . Until very recently, however, only one GPCR structure had been solved, that corresponding to the signaling-off state of bovine rhodopsin (2) . During the past year, we have experienced a revolution in GPCR structural biology, with five additional structures published, including those of the human ␤ 2 -adrenergic receptor (␤ 2 AR) in the absence and presence of an inverse agonist (3, 4) and the turkey ␤ 1 AR complexed with a high-affinity antagonist (5) . Collectively, these structures have opened new vistas for the structural modeling of other receptors, and for the virtual screening of ligand libraries by in silico ligand docking (6) . A new study by Sarkar et al. in this issue of PNAS (7) describes a strategy for engineering GPCRs that may help increase the number of solved structures even further.
The structural analysis of GPCRs poses formidable challenges. Most of these proteins are found in very low abundance in their natural tissues (8) . With the exception of bovine rhodopsin, which can be isolated from retinae, GPCRs have to be expressed and purified from heterologous hosts. For example, protein expressed in insect cells was used for the crystallization of ␤ 1 AR and ␤ 2 AR (3-5). However, heterologous expression typically results in low yields of membrane-integrated receptor, or in protein that is largely inactive. Further, recombinant GPCRs often accumulate in an aggregated state within inclusion bodies, which are challenging to denature, solubilize, and refold (8) . Even when a reasonable expression level of active receptor can be achieved, the instability of GPCRs in detergent micelles and their conformational flexibility make the formation of high-quality diffracting crystals exceedingly difficult (6) . In the case of ␤ 1 AR, useful crystals could only obtained by using a variant with enhanced thermostability in detergent micelles (5) . Similarly, crystallization of ␤ 2 AR was possible only after a highly flexible loop was constrained, either by the use of a specific loopbinding antibody fragment or by its complete replacement with a well folded soluble protein (T4 lysozyme) (3, 4) .
Sarkar et al. (7) describe an elegant strategy for GPCR engineering that promises to kill a number of hard-tocatch birds with one stone, namely, the engineering of GPCRs for: (i) high-yield expression of active protein in a convenient host organism; (ii) enhanced stability in detergent micelles; and (iii) defined ligand selectivity. The authors expressed a large library of variants of the rat neurotensin receptor-1 (NTR1) in the bacterium Escherichia coli and sought to isolate clones exhibiting enhanced ligand binding. NTR1 was expressed as a tripartite fusion to maltosebinding protein and to thioredoxin, both of which are known to prevent aggregation (9, 10) . For the isolation of desired mutants, Sarkar et al. adapted a highthroughput protein-screening methodology called periplasmic expression with cytometric screening (PECS) (11) . In brief, a library of NTR1 mutants was first expressed in E. coli (Fig. 1) . Incubation of the cells in a high-osmolarity buffer allowed a BODIPY-labeled fluorescent conjugate of the oligopeptide neurotensin to cross the permeability barrier that is normally imposed by the bacterial outer membrane and equilibrate into the periplasmic space. Cells expressing NTR1 variants with enhanced ligand-binding activity sequester more ligand and as a result display brighter BODIPY fluorescence (green) than cells producing wild-type (wt) NTR1. These cells can be easily isolated by fluorescence-activated cell sorting (FACS). Sarkar et al. applied three rounds of mutagenesis by error-prone PCR, each followed by four sequential FACS enrichment steps, and the isolated genes were subjected to a fourth round of error-prone PCR and gene shuffling. 
rounds of FACS). A variant NTR1, named D03
, that conferred 10-fold higher cell fluorescence and a corresponding increase in the yield of functional protein relative to the parental NTR1 protein was isolated (7) . The increased yield of functional receptor occurred primarily because the cells synthesized significantly more membraneembedded D03. Interestingly, D03 was shown to also express better in yeast (12-fold increase) and in human cells (3-fold enhancement), indicating that the selected mutations overcame a ratelimiting step in membrane protein insertion common to bacteria and to eukaryotes. Moreover, the purified D03 displayed improved thermostability relative to the parental protein. This finding is intriguing because no evolutionary pressure for thermostability had been imposed. It is possible that enhanced expression might have been conferred by increased resistance to intracellular proteolysis, which in turn often correlates with thermostability (12) . Importantly, higher stability may well prove to facilitate the crystallization of D03.
D03 qualitatively reproduced the G protein-dependent signaling properties of wt NTR1 in human cells. However, an Arg167Leu amino acid substitution prevented D03 from mimicking the pharmacological properties of NTR1 quantitatively. Additionally, the authors used the same screening scheme to identify mutant receptors that exhibited reduced sensitivity to the synthetic neurotensin antagonist SR 48692. Highly fluorescent clones exhibiting neurotensin-BODIPY binding in the presence of 100-fold excess of SR48692 contained a single consensus mutation (Phe358Ser). Interestingly, in earlier studies a Phe358Ala substitution had been shown to lead to decreased antagonist affinity and a lower basal level of NTR1 activity. Phe-358 may be critical for the interaction between transmembrane helices 6 and 7 and for maintaining the receptor in an inactive conformation (13) . Thus, the system developed by Sarkar et al. can also be used to generate engineered GPCR variants with defined selectivity and signaling properties.
The impact of the study by Sarkar et al. (7) extends beyond the engineering of GPCRs. The power of directed evolution as a means of generating proteins with improved properties (including enhanced expression) or with completely new interesting functions is well appreciated (14) , but its application to membrane proteins has been limited by the lack of suitable high-throughput screens. In earlier studies, membrane protein variants with improved expression characteristics (15) , enhanced thermostability in detergents (16) (17) (18) , or ''locking'' of the protein in a specific conformational state (17, 18) , had been isolated from small populations of mutants screened by using labor-intensive assays for expression or ligand binding. By contrast, the system used by Sarkar et al. is versatile and allows the quantitative screening of a very large number of mutants with great speed (Ϸ90,000 cells per sec). The requirements for the implementation of this methodology are that the GPCR under study (or, for that matter, any membrane protein) binds a ligand that can be labeled with a fluorophore and that the target membrane protein does not contain any essential posttranslational modifications that cannot be performed in E. coli. More than 200 human nonolfactory GPCRs with identified ligands are known (1) , and many of these proteins may be amenable to engineering by using this technique. One limitation of this approach is that the isolated GPCR variants need to be expressed in eukaryotic cells to verify that the acquired mutations have not compromised the receptor's signaling properties.
Expression of wild-type NTR1 in E. coli yields only three neurotensin binding sites per cell (9) . The fusion of a N-terminal maltose-binding protein fusion partner results in 450 binding sites per cell (9) , and a C-terminal thioredoxin tag raises this number even further (10) . Similar modifications may be needed to achieve basal expression of other receptors to a level where cells can be labeled with fluorescent ligands. Nonetheless, in principle at least, it may be possible to begin the directed evolution process ''blindly'' even if the parental membrane protein is very poorly expressed and it confers no detectable fluorescent signal above background.
Currently, the expression of GPCRs and other membrane proteins is highly empirical and focuses on the optimization of expression parameters, such as the selection of host strains, growth media, and incubation temperature (8) . Directed evolution techniques will help usher the biochemical community to a new era of GPCR abundance.
